SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Triclabendazole / Abamectin Formulation

Version: 2.1
Revision Date: 2020/12/10
SDS Number: 5341812-00003
Date of last issue: 2020/10/09
Date of first issue: 2019/12/05

1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Triclabendazole / Abamectin Formulation

Manufacturer or supplier’s details
Company: MSD
Address: No. 485 Jing Tai Road
Pu Tuo District - Shanghai - China 200331
Telephone: +1-908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASETeward@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

2. HAZARDS IDENTIFICATION

Emergency Overview
Appearance: suspension
Colour: white
Odour: No data available

May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification
Specific target organ toxicity - repeated exposure: Category 2
Short-term (acute) aquatic hazard: Category 1
Long-term (chronic) aquatic hazard: Category 1

GHS label elements
Hazard pictograms: 

Signal word: Warning

Hazard statements: H373 May cause damage to organs through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements:

**Prevention:**
P260 Do not breathe mist or vapours.
P273 Avoid release to the environment.

**Response:**
P314 Get medical advice/attention if you feel unwell.
P391 Collect spillage.

**Disposal:**
P501 Dispose of contents/container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
May cause damage to organs through prolonged or repeated exposure.

Environmental hazards
Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification
None known.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Substance / Mixture:** Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Triclabendazole</td>
<td>68786-66-3</td>
<td>&gt;= 10 &lt; 20</td>
</tr>
<tr>
<td></td>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>&gt;= 0.0025 &lt; 0.025</td>
</tr>
</tbody>
</table>

### 4. FIRST AID MEASURES

**General advice:**
In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

**If inhaled:**
If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

**In case of skin contact:**
Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

**In case of eye contact:**
Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

**If swallowed:**
If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

**Most important symptoms and effects, both acute and delayed:**
May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
- Nitrogen oxides (NOx)
- Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
7. HANDLING AND STORAGE

Handling
Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage
Conditions for safe storage: Keep in properly labelled containers.
Store in accordance with the particular national regulations.
Materials to avoid: Do not store with the following product types:
Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triclabendazole</td>
<td>68786-66-3</td>
<td>TWA</td>
<td>30 μg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit 100 μg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>30 μg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit 300 μg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.
### Personal protective equipment

**Respiratory protection**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- **Filter type**: Particulates type
- **Eye/face protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**
- Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hand protection**
- **Material**: Chemical-resistant gloves
- **Remarks**: Consider double gloving.

**Hygiene measures**
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>suspension</td>
</tr>
<tr>
<td>Colour</td>
<td>white</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>5.0 - 7.0</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>&lt; 5 °C</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Triclabendazole / Abamectin Formulation

Flammability (solid, gas) : Not applicable
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : 1,050 - 1,080 g/cm³ (20 °C)
Solubility(ies) : soluble
Water solubility : soluble
Partition coefficient: n-octanol/water : Not applicable
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity : Not applicable
Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute dermal toxicity:
Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
Triclabendazole:
Acute oral toxicity:
LD50 (Mouse): > 8,000 mg/kg
LD50 (Rabbit): 206 mg/kg

Acute inhalation toxicity:
LC50 (Rat): > 0.5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity:
LD50 (Rat): > 4,000 mg/kg

Abamectin (combination of avermectin B1a and avermectin B1b):
Acute oral toxicity:
LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity:
LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity:
LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Triclabendazole:
Species: Rabbit
Result: Mild skin irritation

Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Triclabendazole:
Species: Rabbit
Result: No eye irritation

Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.
Respiratory sensitisation
Not classified based on available information.

Components:

Triclabendazole:
Result: Not a skin sensitizer.

Abamectin (combination of avermectin B1a and avermectin B1b):
Test Type: Maximisation Test
Exposure routes: Skin contact
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Triclabendazole:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Abamectin (combination of avermectin B1a and avermectin B1b):
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo:
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Triclabendazole:
Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative

Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:
Triclabendazole:
Effects on fertility:
Test Type: Fertility/early embryonic development
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight  
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 5.5 mg/kg body weight

Effects on foetal development:

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 200 mg/kg body weight  
Result: Effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 50 mg/kg body weight

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 3 mg/kg body weight  
Remarks: Maternal toxicity observed.

Abamectin (combination of avermectin B1a and avermectin B1b):  
Effects on fertility:

Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight  
Result: Fetotoxicity

Effects on foetal development:

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight  
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight  
Result: Cleft palate  
Remarks: Adverse developmental effects were observed
### Triclabendazole / Abamectin Formulation

<table>
<thead>
<tr>
<th>Test Type:</th>
<th>Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rabbit</td>
</tr>
<tr>
<td>Route:</td>
<td>Oral</td>
</tr>
<tr>
<td>LOAEL:</td>
<td>2 mg/kg body weight</td>
</tr>
<tr>
<td>Result:</td>
<td>Cleft palate, Teratogenic effects, Reduced embryonic survival</td>
</tr>
<tr>
<td>Remarks:</td>
<td>Adverse developmental effects were observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type:</th>
<th>Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rat</td>
</tr>
<tr>
<td>Route:</td>
<td>Oral</td>
</tr>
<tr>
<td>LOAEL:</td>
<td>1.6 mg/kg body weight</td>
</tr>
<tr>
<td>Result:</td>
<td>Teratogenic effects</td>
</tr>
</tbody>
</table>

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
May cause damage to organs through prolonged or repeated exposure.

**Components:**

**Triclabendazole:**
- **Target Organs**: Liver, Blood
- **Assessment**: May cause damage to organs through prolonged or repeated exposure.

**Abamectin (combination of avermectin B1a and avermectin B1b):**
- **Exposure routes**: Ingestion
- **Target Organs**: Central nervous system
- **Assessment**: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Triclabendazole:**
- **Species**: Rat
- **NOAEL**: 6.6 mg/kg
- **LOAEL**: 69 mg/kg
- **Application Route**: Oral
- **Exposure time**: 13 Weeks
- **Target Organs**: Blood

- **Species**: Dog
- **NOAEL**: 3.4 mg/kg
- **LOAEL**: 37 mg/kg
Triclabendazole / Abamectin Formulation

Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Liver, Blood

Species: Mouse
NOAEL: 29 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Liver

Species: Rat
NOAEL: 4 mg/kg
Application Route: Oral
Exposure time: 24 Months
Remarks: No significant adverse effects were reported

Abamectin (combination of avermectin B1a and avermectin B1b):

Species: Rat
NOAEL: 1.5 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia

Species: Mouse
NOAEL: 4.0 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia

Species: Dog
NOAEL: 0.25 mg/kg
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Target Organs: Central nervous system
Symptoms: Tremors, weight loss
Remarks: Mortality observed

Species: Monkey
NOAEL: 1.0 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Triclabendazole:
Ingestion: Symptoms: Abdominal pain, Sweating, Headache, Nausea, Vomiting, anorexia, Dizziness, Fatigue, Cough, Fever, pruritus

**Abamectin (combination of avermectin B1a and avermectin B1b):**
Ingestion: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

### 12. ECOLOGICAL INFORMATION

**Ecotoxicity**

**Components:**

**Abamectin (combination of avermectin B1a and avermectin B1b):**

**Toxicity to fish:**
- LC50 (Onchorhynchus mykiss (rainbow trout)): 3.2 µg/l
  Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
  Exposure time: 96 h
- LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
  Exposure time: 96 h
- LC50 (Cyprinus carpio (Carp)): 42 µg/l
  Exposure time: 96 h
- LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
  Exposure time: 96 h

**Toxicity to daphnia and other aquatic invertebrates:**
- EC50 (Americamysis): 0.022 µg/l
  Exposure time: 96 h
- EC50 (Daphnia magna (Water flea)): 0.34 µg/l
  Exposure time: 48 h

**Toxicity to algae/aquatic plants:**
- EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
  Exposure time: 72 h

**M-Factor (Acute aquatic toxicity):** 10,000

**Toxicity to fish (Chronic toxicity):**
- NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
  Exposure time: 32 d

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):**
- NOEC (Daphnia magna (Water flea)): 0.03 µg/l
  Exposure time: 21 d
- NOEC (Mysidopsis baia (opossum shrimp)): 0.0035 µg/l
  Exposure time: 28 d

**M-Factor (Chronic aquatic toxicity):** 10,000

**Toxicity to microorganisms:**
- EC50: > 1,000 mg/l
  Exposure time: 3 h
Test Type: Respiration inhibition

Persistence and degradability

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):
Stability in water: Hydrolysis: 50 % (< 12 h)

Bioaccumulative potential

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):
Bioaccumulation: Bioconcentration factor (BCF): 52
Partition coefficient: n-octanol/water: log Pow: 4

Mobility in soil

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):
Distribution among environmental compartments: log Koc: > 3.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Abamectin (combination of avermectin B1a and avermectin B1b))
Class: 9
Packing group: III
Labels: 9
IATA-DGR
UN/ID No.: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Abamectin (combination of avermectin B1a and avermectin B1b))

Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 964
Packing instruction (passenger aircraft): 964
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))

Class: 9
Packing group: III
Labels: 9
EmS Code: F-A, S-F
Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations
GB 6944/12268
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))

Class: 9
Packing group: III
Labels: 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:
AICS: not determined
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Triclabendazole / Abamectin Formulation

Version 2.1
Revision Date: 2020/12/10
SDS Number: 5341812-00003
Date of last issue: 2020/10/09
Date of first issue: 2019/12/05

DSL: not determined
IECSC: not determined

16. OTHER INFORMATION

Further information

Date format: yyyy/mm/dd

Full text of other abbreviations

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; ICS0 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only
to the specific material identified at the top of this SDS and may not be valid when the SDS mate-
rial is used in combination with any other materials or in any process, unless specified in the text.
Material users should review the information and recommendations in the specific context of their
intended manner of handling, use, processing and storage, including an assessment of the ap-
propriateness of the SDS material in the user’s end product, if applicable.